All In Biotech

Drug Trial Radar · NCT00608985

Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia

Multi-center, Double-blind, Randomized, Placebo-controlled, Active Reference, Parallel-group Polysomnography Study to Assess the Efficacy and Safety of a 16-day Oral Administration of ACT-078573 in Adult Subjects With Chronic Primary Insomnia

Last checked: Nov 19, 2026Latest source record: Mar 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 709 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

709

Actual

Start

Mar 2008

Primary completion

Sep 2009

Study completion Nov 2009

Sponsor

Lead sponsor
Midnight Pharma, LLCIndustry
Sponsor type
Industry
First posted
Feb 6, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A polysomnography study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in adult subjects with primary insomnia.

Conditions

  • Primary Insomnia

Interventions

  • almorexantDrug

    2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem

  • almorexantDrug

    1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem

  • PlaceboDrug

    2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem

  • zolpidemDrug

    2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Day 1&2 in Wake After Sleep Onset (WASO)Time frame: From baseline to Day 1&2
  2. Change From Baseline to Day 15&16 in WASOTime frame: From baseline to Day 15&16
  3. Change From Baseline to Week 1&2 in the Self-reported WASO (sWASO)Time frame: From baseline to Week 1&2

Locations

91 sites in 20 countries. Site status is shown where the registry gives one.

  • The Woolcock Institute of Medical Research

    Glebe, Australia

  • Australian Clinical Research Organisation

    Kippa-Ring, Australia

  • Melbourne Sleep Disorder Centre

    Melbourne, Australia

  • Burnside Hospital Clinical Trials Centre

    Toorak Gardens, Australia

  • Westmead Hospital, Department of Respiratory

    Westmead, Australia

  • Sleep Disorders Laboratory, Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Monash Adult Sleep Center, Monash Medical Centre

    Clayton, Victoria, Australia

  • Western Hospitpal, Private Bag

    Footscray, Victoria, Australia

  • Institute for Breathing and Sleep (IBAS)

    Heidelburg, Victoria, Australia

  • Medical University of Innsbruck, Department of Neurology

    Innsbruck, Austria

  • Rudolfinerhaus

    Vienna, Austria

  • University of Vienna - Department of Neurology

    Vienna, Austria

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • CH Jolimont / Sleep Disorders Center, Hospital de Jolimont

    Haine-Saint-Paul, Belgium

  • Clinique Andre Vesale

    Montigny Le Tilleuil, Belgium

  • Hospital St. Naum, Paediatr. Neurology

    Sofia, Bulgaria

  • MHAT 'St. Marina'

    Varna, Bulgaria

  • Oddeleni nasledne pece, Nemocnice Ceske Budejovice

    České Budějovice, Czechia

  • Centrum pro poruchy spanku a bdeni, Neurologicka klinika

    Katerinska, Czechia

  • Fakultni nemocnice Ostrava/Klinika detske neurologie SLEEP LABORATORY

    Ostava-Poruba, Czechia

  • Poradna pro porchy spanku a spankova, Laborator Unimeds s.r.o.

    Prague, Czechia

  • Somnocentrum Trutnov-spankova laborator, Oddeleni neurologie

    Trutnov, Czechia

  • Scansleep Aps, Sovnlaegecentret

    Aarhus, Denmark

  • Sovnlagecentret - Scan Sleep

    Copenhagen, Denmark

  • Scan Sleep ApS, Sovnlaegecentret

    Copenhagen, Denmark

  • Tutkimuskeskus Vitalmed

    Helsinki, Finland

  • Unesta Research Center

    Tampere, Finland

  • University of Turku, Sleep Research Unit

    Turku, Finland

  • Hopital Pellegrin

    Bordeaux, France

  • Hopital Raymond Poincare

    Garches, France

  • Service de Neurologie B, Hopital Gui de Chauliac

    Montpellier, France

  • Hopital Pitie-Salpetriere

    Paris, France

  • Centre du Sommeil et de la Vigilance, Hopital Hotel Dieu de Paris

    Paris, France

  • Federation des Pathologies du Sommeil

    Paris, France

  • Advanced Sleep Research GmbH

    Berlin, Germany

  • Charite Campus Benjamin Franklin, Klinik und Hochschulambulanz fur Psychiatrie und Psychotherapie

    Berlin, Germany

  • ClinPharm International GmbH Berlin

    Berlin, Germany

  • Klinische Forschung Berlin GmbH

    Berlin, Germany

  • St. Hedwig-Krnkenhaus

    Berlin, Germany

  • ClinPharm International GmbH Bochum

    Bochum, Germany

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.